The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  Corsini, Lidia Rita ^a   Bronte, Giuseppe ^a   Terrasi, Marianna ^a   Amodeo, Valeria ^a   Fanale, Daniele ^a   Fiorentino, Eugenio ^b   Cicero, Giuseppe ^b   Bazan, Viviana ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

biomarkers; cancer; miRNAs; therapy

Indexed keywords

2' O METHYL ANTISENSE OLIGONUCLEOTIDE; ANTI MIRNA OLIGONUCLEOTIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; MICRORNA; SMALL MOLECULE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BIOGENESIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CANCER TISSUE; DRUG TARGETING; GENE EXPRESSION; HEPATITIS C; HUMAN; NONHUMAN; ONCOGENE; TUMOR SUPPRESSOR GENE;

HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858975779     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.650632     Document Type: Article

References (60)

1. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009;60:167-79
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
3. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007;6(17):2127-32 (Pubitemid 47450412)
4. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10(10):704-14
5. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008;14(2):360-5 (Pubitemid 351226101)
6. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99(24):15524-9 (Pubitemid 35403967)
7. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9(3):189-98 (Pubitemid 43357945)
8. Li C, Kim SW, Rai D, et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009;113(26):6681-90
9. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008;105(19):7004-9 (Pubitemid 351754520)
10. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006;103(24):9136-41 (Pubitemid 43902545)
11. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol cancer 2010;9:306
12. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev 2006;6(11):857-66 (Pubitemid 44629897)
13. Li M, Marin-Muller C, Bharadwaj U, et al. MicroRNAs: control and loss of control in human physiology and disease. World J Surg 2009;33(4):667-84
14. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6(4):259-69 This review is of considerable importance because it highlights the miRNAs' role as tumor suppressors and oncogenes that might prove useful in the diagnosis and treatment of cancer.
15. Sotillo E, Thomas-Tikhonenko A. Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther 2011;131(1):18-32
16. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13(1):39-53
17. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65(14):6029-33 (Pubitemid 40994386)
18. Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011;1812(5):592-601
19. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120(5):635-47 (Pubitemid 40343076)
20. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell cycle 2008;7(6):759-64 (Pubitemid 351520040)
21. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010;8(5):629-42
22. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009;69(19):7495-8
23. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010;59(7):1794-802
24. Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010;29(29):4237-44
25. Iorio MV, Casalini P, Tagliabue E, et al. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 2008;44(18):2753-9
26. Shen J, Ambrosone CB, DiCioccio RA, et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008;29(10):1963-6
27. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26(4):462-9 (Pubitemid 351501813)
28. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRTPCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23(6):814-23
29. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18(10):997-1006
30. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67(24):11612-20
31. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010;251(3):499-505
32. Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin chem 2011;57(1):84-91
33. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105(30):10513-18
34. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127(1):118-26
35. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58(10):1375-81
36. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplifiedfrom plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010;25(10):1674-80
37. Fabbri M. miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn 2010;10(4):435-44
38. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27(34):5848-56
39. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42(8):1273-81 This review is important because it summarizes the most significant and latest findings of original researches on miRNAs involved in cancer.
40. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13(1):48-57
41. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54(10):1696-704
42. Lee JH, Voortman J, Dingemans AM, et al. MicroRNA expression and clinical outcome of small cell lung cancer. PloS One 2011;6(6):e21300
43. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451(7175):147-52
44. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96(2):111-15 (Pubitemid 40425386)
45. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359(25):2641-50
46. Cortes-Sempere M, Ibanez de Caceres I. microRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol 2011;13(6):357-62
47. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009;125(11):2737-43
48. Cho WC. Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance. Expert Rev Mol Diagn 2011;11(7):691-4
49. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006;13(6):496-502 This review is important because it summarizes the main approaches that can interfere with miRNA function in vitro and in vivo, evaluating the potential miRNAs' use for therapeutic strategies.
50. Petersen M, Bondensgaard K, Wengel J, Jacobsen JP. Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids. J Am Chem Soc 2002;124(21):5974-82 (Pubitemid 34555398)
51. Frieden M, Hansen HF, Koch T. Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids 2003;22(5-8):1041-3 (Pubitemid 37139318)
52. Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003;42(26):7967-75 (Pubitemid 36807714)
53. Grunweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs 2007;21(4):235-43 This review is particularly important because by comparing the locked nucleic acid oligonucleotides with other RNA interference technologies, it explains the benefits of the possible in vivo application of LNA such antisense target. (Pubitemid 47104979)
54. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Investig 2010;120(4):1298-309
55. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (New York, NY) 2010;327(5962):198-201 This work is very important because it shows the most recent results obtained using strategies based on silencing of miRNAs in primates with chronic hepatitis C virus infection. This results showing no evidence of side effects in the treated animals suggest a therapeutic role of this strategies in other human disease such cancer.
56. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34(8):2294-304 (Pubitemid 43985667)
57. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007;26(19):2799-803 (Pubitemid 46663837)
58. Gumireddy K, Young DD, Xiong X, et al. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 2008;47(39):7482-4
59. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19(6):1116-22
60. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008;105(10):3903-8 (Pubitemid 351723497)